Literature DB >> 16740798

The cancer and leukemia group B transplant committee.

Charles Linker1, David Hurd.   

Abstract

The Transplant Committee of the Cancer and Leukemia Group B has a robust portfolio of studies and is poised to make significant contributions to the field. We are working in collaboration with the Cancer and Leukemia Group B Leukemia and Lymphoma Disease Committees and importantly in collaboration with other groups to define the role of both autologous and reduced-intensity allogeneic transplantation in the management of selected hematologic malignancies. Some of our studies have the potential to change the standard of care in areas such as the maintenance therapy for multiple myeloma after autologous transplantation and to generate the data that could lead to acceptance of new approaches to the initial post-remission therapy of older adults with acute myeloid leukemia. The cooperative group setting allows us to advance the transplant field by showing which approaches are successful outside of single institutions and are therefore feasible on a generalized basis.

Entities:  

Mesh:

Year:  2006        PMID: 16740798     DOI: 10.1158/1078-0432.CCR-06-9012

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  1 in total

Review 1.  Tomorrow's cancer treatments today: the first 50 years of the Cancer and Leukemia Group B.

Authors:  Mark R Green; Stephen L George; Richard L Schilsky
Journal:  Semin Oncol       Date:  2008-10       Impact factor: 4.929

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.